



(11) **EP 2 095 825 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 72**
- (48) Corrigendum issued on:  
**28.03.2012 Bulletin 2012/13**
- (45) Date of publication and mention of the grant of the patent:  
**22.06.2011 Bulletin 2011/25**
- (21) Application number: **06843990.0**
- (22) Date of filing: **28.11.2006**
- (51) Int Cl.:  
**A61K 38/47 (2006.01) A61K 9/02 (2006.01)**  
**A61K 9/20 (2006.01) A61K 9/48 (2006.01)**  
**A61K 9/68 (2006.01) A61P 43/00 (2006.01)**
- (86) International application number:  
**PCT/RU2006/000642**
- (87) International publication number:  
**WO 2008/066403 (05.06.2008 Gazette 2008/23)**

(54) **METHOD FOR TREATING HUMAN DISEASES ASSOCIATED WITH AN INCREASED DEOXYRIBONUCLEIC ACID CONTENT IN EXTRACELLULAR SPACES OF TISSUES AND A MEDICINAL PREPARATION FOR CARRYING OUT SAID METHOD**

VERFAHREN ZUR BEHANDLUNG VON KRANKHEITEN DES MENSCHEN IM ZUSAMMENHANG MIT EINEM ERHÖHTEN DESOXYRIBONUCLEINSÄUREGEHALT IN EXTRAZELLULÄREN RÄUMEN VON GEWEBEN UND MEDIZINISCHE ZUBEREITUNG ZUR DURCHFÜHRUNG DES VERFAHRENS

PROCÉDÉ DE TRAITEMENT DE MALADIES HUMAINES ACCOMPAGNÉES D'UNE TENEUR PLUS ÉLEVÉE D'ADN DANS DES ESPACES INTERCELLULAIRES ET PRÉPARATION MÉDICAMENTEUSE DESTINÉE À SA MISE EN OEUVRE

- (84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR**
- (43) Date of publication of application:  
**02.09.2009 Bulletin 2009/36**
- (73) Proprietor: **CLS Therapeutics Limited**  
**Guernsey GY1 3DR (GB)**
- (72) Inventors:  
• **GENKIN, Dmitry Dmitrievich**  
**197110, Saint-Petersburg (RU)**  
• **TETS, Viktor Veniaminovich**  
**196066, Saint -Petersburg (RU)**  
• **TETS, Georgy Viktorovich**  
**191040, Saint -Petersburg (RU)**
- (74) Representative: **Gulde Hengelhaupt Ziebig & Schneider**  
**Patentanwälte - Rechtsanwälte**  
**Wallstrasse 58/59**  
**10179 Berlin (DE)**
- (56) References cited:  
**EP-A1- 1 655 036 WO-A1-95/00170**  
**WO-A1-97/47751 WO-A2-2005/115444**  
**GB-A- 1 005 985 RU-C1- 2 207 876**  
**US-A- 5 484 589 US-A1- 2003 044 403**  
**US-A1- 2004 157 239**
- **DATABASE PUBMED [Online] VONMOOSP.L. ET AL.: 'Absorption and hematologic effect of streptokinase-streptodornase (varidase) after intracavitary or oral administration', XP008110204 Database accession no. (394315) & SCHWEIZ MED WOCHENSCHR vol. 109, no. 41, 27 October 1979, pages 1538 - 1544**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 095 825 B8**